Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites

Verfasser / Beitragende:
[Tetsuya Ito, Norio Hanafusa, Satoru Iwase, Eisei Noiri, Masaomi Nangaku, Keiichi Nakagawa, Kiyoshi Miyagawa]
Ort, Verlag, Jahr:
2015
Enthalten in:
International Journal of Clinical Oncology, 20/3(2015-06-01), 623-628
Format:
Artikel (online)
ID: 605491003
LEADER caa a22 4500
001 605491003
003 CHVBK
005 20210128100507.0
007 cr unu---uuuuu
008 210128e20150601xx s 000 0 eng
024 7 0 |a 10.1007/s10147-014-0750-y  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s10147-014-0750-y 
245 0 0 |a Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites  |h [Elektronische Daten]  |c [Tetsuya Ito, Norio Hanafusa, Satoru Iwase, Eisei Noiri, Masaomi Nangaku, Keiichi Nakagawa, Kiyoshi Miyagawa] 
520 3 |a Background: It is expected that cell-free and concentrated ascites reinfusion therapy (CART) will relieve the symptoms caused by ascites. To date, however, no report of objective changes in patients' symptoms has been published. We have therefore evaluated symptom management by CART. Methods: From April 2011 to July 2012, 37 patients at our hospital, most of whom had malignancies, received CART. Symptom severity was evaluated in each patient 24 h before and after the first CART procedure using a numerical rating scale for abdominal tension and the Japanese version of the M. D. Anderson Symptom Inventory (MDASI-J) for various symptoms. Results: CART significantly improved the scores for abdominal tension and the symptom and interference scores of the MDASI-J within 24 h of the procedure. The abdominal tension scores decreased from 7.19 to 3.81 (p<0.001), the symptom scores of the MDASI-J decreased from 4.73 to 2.75 and the interference scores of the MDASI-J decreased from 7.05 to 5.12. Detailed investigation revealed many symptoms, including fatigue and gastric symptoms, which are the usual targets of paracentesis, as well as general symptoms. No significant correlation between improved scores and the amount of reinfused protein or ascites removed was observed. Patients experienced no severe adverse event. Conclusions: Among the 37 patients receiving CART, various symptoms related to malignant ascites, especially fatigue, improved within the 24-h period following CART. Factors that ameliorate these symptoms remain to be elucidated. 
540 |a Japan Society of Clinical Oncology, 2014 
690 7 |a Cell-free and concentrated ascites reinfusion therapy  |2 nationallicence 
690 7 |a Numerical rating scale  |2 nationallicence 
690 7 |a Ascites  |2 nationallicence 
690 7 |a Malignancy  |2 nationallicence 
690 7 |a Symptom relief  |2 nationallicence 
690 7 |a MDASI-J  |2 nationallicence 
700 1 |a Ito  |D Tetsuya  |u Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
700 1 |a Hanafusa  |D Norio  |u Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
700 1 |a Iwase  |D Satoru  |u Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
700 1 |a Noiri  |D Eisei  |u Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
700 1 |a Nangaku  |D Masaomi  |u Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
700 1 |a Nakagawa  |D Keiichi  |u Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
700 1 |a Miyagawa  |D Kiyoshi  |u Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
773 0 |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/3(2015-06-01), 623-628  |x 1341-9625  |q 20:3<623  |1 2015  |2 20  |o 10147 
856 4 0 |u https://doi.org/10.1007/s10147-014-0750-y  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s10147-014-0750-y  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ito  |D Tetsuya  |u Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Hanafusa  |D Norio  |u Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Iwase  |D Satoru  |u Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Noiri  |D Eisei  |u Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Nangaku  |D Masaomi  |u Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Nakagawa  |D Keiichi  |u Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Miyagawa  |D Kiyoshi  |u Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/3(2015-06-01), 623-628  |x 1341-9625  |q 20:3<623  |1 2015  |2 20  |o 10147